Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITY OF SHEFFIELD currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners and 3 distinct art units. This distribution indicates a fragmented prosecution landscape for the university.
RIDDER, CLAYTON PAUL is the busiest examiner for this portfolio, managing 1 pending office action. The involvement of 3 distinct examiners and 3 distinct art units means that each pending matter is being handled by a different person in a different technical group.
For practitioners, the 3 pending office actions require managing separate examiner relationships across 3 different art units. Since RIDDER, CLAYTON PAUL and the other examiners each have a single pending action, there is no concentration of workload. This distribution suggests that the university's biotechnology and pharmaceutical filings cover a variety of distinct technical sub-sectors, necessitating a multifaceted strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RIDDER, CLAYTON PAUL | 1 | 67.7% | +25.4% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17909318 | ANTIMICROBIAL TARGET | BERRY, LAYLA D | 121d overdue |
| 17910125 | GENE THERAPY TREATMENT | SINGH, ANOOP KUMAR | 14d |
| 18878114 | OBJECT LOCALISATION | RIDDER, CLAYTON PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17910125 | GENE THERAPY TREATMENT | SINGH, ANOOP KUMAR | 14d |
| 18878114 | OBJECT LOCALISATION | RIDDER, CLAYTON PAUL | — |
| Art Unit | Apps |
|---|---|
| 3646 | 1 |
| 1632 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18878114 | OBJECT LOCALISATION | RIDDER, CLAYTON PAUL | 3646 | §103§112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 17910125 | GENE THERAPY TREATMENT | SINGH, ANOOP KUMAR | 1632 | §102§103§112 | Non-Final OA | 14d | Pending | Sep 08, 2022 |
| 17909318 | ANTIMICROBIAL TARGET | BERRY, LAYLA D | 1693 | §102§103§112 | Final Rejection | 121d overdue | Pending | Sep 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial